Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Michael Bishop

Concepts (172)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Osteosarcoma
15
2024
45
4.740
Why?
Bone Neoplasms
17
2024
178
4.250
Why?
Sarcoma, Ewing
6
2024
27
1.980
Why?
Neuroblastoma
5
2021
51
1.470
Why?
Antibodies, Monoclonal, Humanized
4
2021
224
1.040
Why?
Antineoplastic Combined Chemotherapy Protocols
7
2024
997
0.950
Why?
Induction Chemotherapy
4
2021
59
0.860
Why?
Child, Preschool
18
2024
3953
0.760
Why?
Child
26
2024
6931
0.750
Why?
Adolescent
25
2024
6453
0.750
Why?
Young Adult
19
2023
4075
0.600
Why?
Nuclear Proteins
2
2024
235
0.590
Why?
Neoplasms
7
2022
1246
0.580
Why?
Radionuclide Imaging
1
2016
116
0.500
Why?
Sarcoma
3
2024
65
0.500
Why?
Immunotherapy
2
2021
231
0.480
Why?
Molecular Targeted Therapy
1
2016
122
0.470
Why?
Desmoplastic Small Round Cell Tumor
3
2019
4
0.460
Why?
Hematopoietic Stem Cell Transplantation
1
2020
580
0.460
Why?
Lung Neoplasms
2
2020
597
0.460
Why?
Male
28
2024
25867
0.450
Why?
Prognosis
7
2021
1974
0.450
Why?
Adult
21
2022
13561
0.440
Why?
Oncogene Proteins
1
2014
16
0.440
Why?
Female
28
2024
27053
0.430
Why?
Adrenal Gland Neoplasms
1
2014
51
0.420
Why?
Survivors
4
2022
126
0.400
Why?
Humans
38
2024
50417
0.400
Why?
Bone and Bones
1
2016
481
0.390
Why?
Retrospective Studies
14
2024
6274
0.370
Why?
Liver Neoplasms
2
2018
321
0.360
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
2
2021
56
0.350
Why?
Neoplasm Recurrence, Local
5
2021
622
0.330
Why?
Peritoneal Neoplasms
3
2019
63
0.320
Why?
Hyperthermia, Induced
2
2019
115
0.280
Why?
Cohort Studies
6
2020
1451
0.270
Why?
Pain
2
2020
386
0.270
Why?
Cognition Disorders
2
2020
211
0.260
Why?
Methotrexate
2
2017
76
0.250
Why?
Follow-Up Studies
6
2021
2231
0.250
Why?
Combined Modality Therapy
4
2020
640
0.240
Why?
Survival Rate
4
2020
906
0.230
Why?
Rhabdoid Tumor
1
2024
11
0.230
Why?
Wilms Tumor
1
2024
18
0.230
Why?
Negative-Pressure Wound Therapy
1
2024
11
0.220
Why?
Treatment Outcome
7
2024
5265
0.220
Why?
Neoadjuvant Therapy
1
2024
119
0.210
Why?
Risk Factors
6
2021
3712
0.200
Why?
Kidney Neoplasms
1
2024
174
0.200
Why?
DNA Helicases
1
2024
147
0.200
Why?
Chemotherapy, Adjuvant
3
2019
119
0.200
Why?
Interleukin-2
1
2021
70
0.190
Why?
Prospective Studies
4
2021
2378
0.190
Why?
Infant
6
2024
3648
0.190
Why?
Survival Analysis
2
2020
658
0.180
Why?
Hypothyroidism
1
2021
56
0.180
Why?
Transcription Factors
1
2024
561
0.180
Why?
Phthalazines
1
2020
20
0.170
Why?
Quality of Life
4
2021
850
0.170
Why?
Salvage Therapy
1
2021
137
0.170
Why?
Central Nervous System Neoplasms
1
2021
61
0.170
Why?
Leukemia, Myeloid, Acute
1
2021
180
0.160
Why?
Leydig Cells
1
2019
7
0.160
Why?
Fluorodeoxyglucose F18
2
2023
187
0.160
Why?
Radiotherapy
2
2017
125
0.160
Why?
Epigenomics
1
2019
65
0.160
Why?
Brachytherapy
1
2019
46
0.150
Why?
Chemotherapy, Cancer, Regional Perfusion
1
2018
6
0.150
Why?
Drug Resistance, Neoplasm
1
2021
315
0.150
Why?
Alanine Transaminase
1
2018
117
0.150
Why?
Anesthetics
1
2018
36
0.150
Why?
Genetic Predisposition to Disease
2
2024
507
0.150
Why?
Transplantation, Autologous
1
2020
480
0.140
Why?
Genomics
1
2019
238
0.140
Why?
Chronic Disease
1
2020
573
0.140
Why?
Risk Assessment
5
2021
1268
0.140
Why?
Primary Ovarian Insufficiency
1
2017
5
0.140
Why?
Hand-Foot Syndrome
1
2017
1
0.140
Why?
Thoracic Wall
1
2017
9
0.140
Why?
Chile
1
2017
4
0.140
Why?
Thoracic Neoplasms
1
2017
13
0.140
Why?
Cytarabine
1
2017
37
0.140
Why?
Pain Management
1
2018
180
0.140
Why?
Cost of Illness
1
2017
115
0.130
Why?
Health Resources
1
2017
74
0.130
Why?
Karyotype
1
2016
17
0.130
Why?
Antimetabolites, Antineoplastic
1
2016
35
0.130
Why?
Radiation Injuries
1
2017
112
0.120
Why?
Cell Line, Tumor
1
2020
1392
0.120
Why?
Hematologic Neoplasms
1
2017
99
0.120
Why?
Urogenital Neoplasms
1
2015
9
0.120
Why?
Neurotoxicity Syndromes
1
2016
45
0.120
Why?
Proportional Hazards Models
1
2016
416
0.120
Why?
Forecasting
1
2015
144
0.110
Why?
Chromosome Aberrations
1
2016
279
0.110
Why?
Organ Sparing Treatments
1
2014
56
0.110
Why?
Disease Management
1
2015
179
0.110
Why?
Rats
1
2020
3262
0.110
Why?
Cross-Sectional Studies
4
2021
1601
0.110
Why?
Infant, Newborn, Diseases
1
2014
56
0.100
Why?
Cognition
1
2016
342
0.100
Why?
United States
3
2018
5005
0.100
Why?
Prevalence
3
2021
967
0.100
Why?
Infant, Newborn
2
2017
2752
0.090
Why?
Neoplasm Staging
2
2023
738
0.080
Why?
Animals
2
2020
13062
0.070
Why?
Time Factors
3
2021
2933
0.070
Why?
Disease-Free Survival
2
2019
439
0.060
Why?
Age Factors
2
2021
1118
0.060
Why?
Middle Aged
5
2019
12579
0.060
Why?
Postoperative Complications
2
2024
1030
0.060
Why?
Databases, Factual
2
2018
676
0.060
Why?
Germ-Line Mutation
1
2024
61
0.060
Why?
Femoral Neoplasms
1
2024
8
0.060
Why?
Limb Salvage
1
2024
40
0.050
Why?
Nephrectomy
1
2024
78
0.050
Why?
Femur
1
2024
130
0.050
Why?
Surgical Wound Infection
1
2024
115
0.050
Why?
Radiopharmaceuticals
1
2023
202
0.050
Why?
Tumor Burden
1
2021
130
0.050
Why?
Positron-Emission Tomography
1
2023
290
0.050
Why?
Antineoplastic Agents
2
2020
1165
0.050
Why?
Ifosfamide
1
2021
11
0.040
Why?
Maximum Tolerated Dose
1
2021
39
0.040
Why?
Vincristine
1
2021
82
0.040
Why?
Tissue Distribution
1
2021
167
0.040
Why?
Length of Stay
1
2024
631
0.040
Why?
Gangliosides
1
2019
4
0.040
Why?
Luteinizing Hormone
1
2019
49
0.040
Why?
Anthracyclines
1
2020
29
0.040
Why?
Protein Kinase Inhibitors
1
2021
204
0.040
Why?
Doxorubicin
1
2021
235
0.040
Why?
Testosterone
1
2019
145
0.040
Why?
Killer Cells, Natural
1
2019
107
0.040
Why?
Clinical Trials as Topic
1
2021
488
0.040
Why?
Radiotherapy, Adjuvant
1
2018
63
0.040
Why?
Kaplan-Meier Estimate
1
2019
462
0.040
Why?
Rare Diseases
1
2018
43
0.040
Why?
Epigenesis, Genetic
1
2021
371
0.040
Why?
Tumor Suppressor Protein p53
1
2019
212
0.040
Why?
Tennessee
1
2017
37
0.030
Why?
Parity
1
2017
43
0.030
Why?
Radiodermatitis
1
2017
5
0.030
Why?
Neoplasm, Residual
1
2018
161
0.030
Why?
Antineoplastic Agents, Alkylating
1
2017
73
0.030
Why?
Ovary
1
2017
114
0.030
Why?
Sex Distribution
1
2017
135
0.030
Why?
Age Distribution
1
2017
172
0.030
Why?
Antibodies, Monoclonal
1
2021
459
0.030
Why?
Infusions, Intravenous
1
2017
212
0.030
Why?
Proteomics
1
2019
313
0.030
Why?
Scoliosis
1
2017
60
0.030
Why?
Drug Administration Schedule
1
2017
373
0.030
Why?
Radiation Dosage
1
2017
162
0.030
Why?
Analysis of Variance
1
2017
549
0.030
Why?
Osteoporosis
1
2017
156
0.030
Why?
Multivariate Analysis
1
2017
583
0.030
Why?
Odds Ratio
1
2017
550
0.030
Why?
Memory
1
2016
110
0.030
Why?
Executive Function
1
2016
75
0.030
Why?
Attention
1
2016
165
0.030
Why?
Morbidity
1
2015
130
0.030
Why?
Extremities
1
2014
30
0.030
Why?
Emotions
1
2016
167
0.030
Why?
Body Mass Index
1
2017
674
0.030
Why?
Biopsy
1
2016
588
0.030
Why?
Incidence
1
2017
1027
0.030
Why?
Severity of Illness Index
1
2017
976
0.030
Why?
Dose-Response Relationship, Drug
1
2017
1369
0.030
Why?
Mutation
1
2019
1275
0.030
Why?
Case-Control Studies
1
2016
1152
0.020
Why?
Mice
1
2020
5658
0.020
Why?
Bishop's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Similar People Expand Description
_
Same Department Expand Description